Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018

March 2, 2018 7:00 AM

BOSTON, March 2, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 8, 2018, to discuss the financial results for the fourth quarter and twelve months ended December 31, 2017, as follows:


March 8, 2018


8:30 a.m. EST

Dial-in numbers:

Toll free: (1-866-374-4635) (U.S.), (1-855-669-9657) (Canada), or

International: (1-412-902-4218)

Audio webcast (live & archive):, under 'Investors' or click here.

The teleconference replay will be available approximately one hour after completion through Thursday, March 15, 2018, at 1-877-344-7529 (U.S.), 1-855-669-9658 (Canada) or 1-412-317-0088 (International). The replay access code is 10117499.

The archived webcast will be available for one year via the aforementioned URLs.

About Juniper PharmaceuticalsJuniper Pharmaceuticals, Inc.'s core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. The Company is also leveraging its differentiated intravaginal ring technology, which offers the potential to address unmet needs in women's health. Please visit for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.

Investor Contact: Laura Perry or Heather Savelle Argot Partners

To receive Juniper's press releases, SEC filings or calendar alerts by email click here. Follow us on LinkedIn

Juniper Pharmaceuticals, Inc.

Cision View original content with multimedia:

SOURCE Juniper Pharmaceuticals, Inc.


Press Releases